• Asian Pacific Journal of Cancer Prevention
• /
• 제15권20호
• /
• pp.8937-8939
• /
• 2014

The aim of this study is to determine results of high prostate specific antigen (PSA) or abnormal digital rectal examination driven prostate biopsies performed in our Department in men aged 75 or more and to show the characteristics of pathology results. The hospital records of the patients who had high PSA or abnormal digital rectal examination driven prostate biopsy in two common university based research hospitals have been reviewed retrospectively. Patients aged 75 years or older at the date of biopsy whose records provided pathology results and full medical history were evaluated for the study. A total of 103 patients were evaluated with a mean age of $79.4{\pm}3.4years$. More than half of the patients (55.1%) were in their seventh decade and the rest were in the eighth decade. Median PSA value was 15.0 (range 2.1-4500) ng/ml. In most of the biopsies (67%), PSA levels were lower than 20 ng/ml. In almost half of the patients (48%), digital rectal examination was abnormal. In 68.9% of the patients, there were at least one or more associated co-morbid diseases. Gleason scores were 7 or higher in 73%, and 8 or higher in 37% of the patients with prostate cancer. Four of the 70 (6%) patients had bone metastases. Castrations were applied to most of the patients with prostate adenocarcinoma (%79). High percentage of high grade (Gleason 7 or more) prostate adenocarcinoma in the elderly refutes the perception of prostate cancer in this age group as clinically insignificant. Therefore, it is to be kept in mind that prostate cancer in the elderly an be clinically significant and prostate biopsies are to be performed when necessary.

• 한국버섯학회지
• /
• 제13권3호
• /
• pp.181-184
• /
• 2015

버섯은 영양소 및 풍미가 뛰어나 오래전부터 식재료로 널리 활용되고 있으며 항염증 및 항산화효능도 뛰어난 것으로 알려져 있다. 그러나 버섯의 항산화 효능은 아직 연구가 미비한 실정이다. 따라서 본 연구에서는 버섯의 항전립선암 효능을 분석하였다. 이를 위해, 식용버섯인 참송이버섯, 꽃송이버섯, 편각영지버섯, 녹각영지, 현미동충하초버섯, 잎새버섯, 석이버섯, 상황버섯 등 8종 버섯의 열수 추출물에 대한 항전립선암 효능을 전립선암 세포주인 LNCaP에서 확인한 결과 참송이버섯, 편각영지버섯 및 현미동충하초버섯이 PSA 발현을 저해하는 효능이 탁월한 것을 확인하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권18호
• /
• pp.7781-7784
• /
• 2014

Background: The aims of this study were to investigate the utility of red blood cell distribution width (RDW) as a simple and readily available marker in prostate cancer, as well as to evaluate RDW as a predictor of progression in prostate cancer patients. Materials and Methods: We evaluated 62 newly diagnosed prostate cancer patients who underwent transrectal ultrasound (TRUS)-guided biopsy and 62 healthy controls of mean age 64 (range, 45-75) years at the Urology Clinic of Bozok University Hospital. Data collection was performed using our laboratory information system database to retrieve findings regarding RDW, hemoglobin, prostatespecific antigen (PSA), and age. The RDW values were compared between the healthy control group and prostate cancer patients. A high risk of progression as defined as a Gleason score (GS) >6, total number of cores positive for cancer >33%, each core containing >50% cancer cells, and a prostate-specific antigen (PSA) level >10 ng/mL. Patients were classified according to risk of progression, as well as divided into subgroups according to the RDW quartile. Results: The mean RDW value of prostate cancer patients was 14.6, compared with 13.7 in the healthy control group (p=0.001). A higher RDW was associated with an increased risk of progression, whereas a lower RDW value was correlated with a low risk of progression. Conclusions: RDW is an easily derived measure that might, in combination with other markers, help predict prostate cancer risk and progression. We suggest that RDW may be used in combination with other parameters in the assessment of prostate cancer.

• 한국식품영양과학회지
• /
• 제43권4호
• /
• pp.507-515
• /
• 2014

본 연구는 전립선암세포주인 LNCaP 세포주와 테스토스테론으로 유도된 전립선비대 백서모델에서 복분자 추출물의 전립선비대 억제 효과를 조사하였다. 첫째, 전립선암 세포주(LNCaP)에서 복분자 미숙과 추출물의 안드로겐 관련 전립선비대 유전자 억제 효과를 조사한 결과 미숙과 50% 에탄올 추출물은 안드로겐 수용체(AR)뿐만 아니라 전립선특이항원(PSA)과 5-알파 환원 효소 type 2(5AR2)의 발현을 가장 높게 억제하였다. 또한 LNCaP 세포에 DHT로 안드로겐 관련 유전자를 유도한 후 복분자 미숙과 50% 에탄올 추출물을 처리한 결과 AR과 PSA mRNA의 발현이 억제됨을 확인하였다. 둘째, 테스토스테론을 이용하여 전립선비대를 유도한 동물모델에서 복분자 미숙과 50% 에탄올 추출물을 6주간 투여한 후 전립선비대 개선 효과를 조사한 결과, 전립선비대유발군에 복분자 미숙과 추출물을 투여한 군에서 전립선 무게, 전립선 소포의 상피세포 두께 및 면적이 감소함을 확인할 수 있었고, 전립선비대 유발 호르몬인 DHT level이 감소함을 확인할 수 있었다.

• Journal of Gastric Cancer
• /
• 제14권2호
• /
• pp.135-137
• /
• 2014

Metastasis of gastric adenocarcinoma to the prostate gland is extremely rare. Herein, we report a case of gastric adenocarcinoma in a 56-year-old man with prostatic metastasis diagnosed through the analysis of biopsy specimens from representative lesions in the stomach and prostate gland. Immunohistochemistry of the prostatic tissue showed positive staining for cytokeratin 7 and negative staining for prostate-specific antigen (PSA), whereas the serum PSA level was normal, confirming the diagnosis of prostatic metastasis from carcinoma of the stomach.

• 보건교육건강증진학회지
• /
• 제30권4호
• /
• pp.99-110
• /
• 2013

Objectives: This study aimed to investigate factors related to prostate disease and follow-up procedure on health examination program in Gangwon-do. Methods: The studied population was 16,501 male aged 40 or more, who underwent screening tests for prostatic disease in 2011 health examination program designed for the low income residents in Gangwon-do. The screening tests included prostate specific antigen (PSA), international symptom score (IPSS), and maximal flow rate (Qmax). We conducted chi-square test for trend, two independent samples t-test, and binary logistic regression to find out the relationship between prostate cancer or benign prostatic hyperplasia and risk factors such as age, PSA level, and IPSS. Results: The number of subjects who turned out positive for PSA level (> 3.8ng/ml) was 971 men accounting for 5.9%. The result of post survey on them showed that 511 subjects (52.6%) got the urology check-up: 156 (30.5%) were diagnosed as normal, 286 (56.0%) as benign prostatic hyperplasia, and 69 (13.5%) as prostate cancer. The detection rate for prostate cancer was 8.8% when PSA level was between 3.81 and 9.99g/ml, and was 30.6% when PSA level was more than 10.00ng/ml. The rates of further testing varied depending on the communities from 26.7% to 68.2%, which was mainly affected by the role of local health center. Conclusions: Our findings indicate that enhanced quality control of local health center and empowerment of screening agency would increase the effort of coupled institutions between public and private sectors.

• 한국식품영양과학회지
• /
• 제33권8호
• /
• pp.1294-1301
• /
• 2004

본 연구에서는 전립선암 환자를 대상으로 이소플라본 보충제 섭취가 혈중 PSA 농도, 지질 패턴, 면역체계 및 항산화체계에 미치는 영향에 대하여 검토하고자 하였다. 전립선암환자에 게 하루 150 mg의 이소플라본을 섭취시킨 결과, 이소플라본 섭취 전에 비해 소변 내 이소플라본의 배설량이 유의적으로 증가하였다. PSA(prostate specific antigen)의 경우는 이소플라본 섭취 전보다 섭취 2달 후에 약간 증가함을 보였으나 유의적인 수준은 아니었다. 이소플라본 섭취가 전립선암 환자의 혈청 지질패턴에 미치는 영향에 대한 분석결과, 총 콜레스테롤의 경우 이소플라본 섭취 시작 전에 비해 섭취 2달 후에 유의적으로 감소되었으며, LDL 콜레스테롤의 경우 이소플라본 섭취 2달 후에 감소하는 경향을 보였으나 유의적인 차이를 보이지 않았고, HDL 콜레스테롤 수준에는 변화가 없는 것으로 나타났다. IL-6의 경우, 이소플라본 섭취 전에 비해 이소플라본 섭취 후에 수치가 감소하였고, VEGF와 TNF-$\alpha$는 이소플라본 섭취 전보다 섭취 2개월 후에 증가하였으나 유의적인 차이를 보이지는 않았다. 이소플라본 섭취전ㆍ후의 총항산화력을 TAS를 통해 측정한 결과 이소플라본 투여 전에 비 해 투여 2개월 후 수치가 증가하였으나 통계적으로 유의적인 차이는 보이지 않았다. 또한 혈액에서 분리된 임파구의 DNA 손상 정도를 측정하기 위해 comet assay를 시도한 결과 tail moment (TM)의 경우 이소플라본 섭취 2달 후에 감소하였으나 유의적인 차이는 없었으며, tail length(TL)의 경우는 유의적으로 감소하였다. 본 연구의 제한점으로는 연구 대상자의 수가 적었으며, 실험 결과를 비교할 대조군이 없었고, 연구기간이 짧다는 것을 들 수 있다. 따라서 이번 연구에서 이소플라본이 전립선암에 기대되는 효과를 보여주기엔 미비한 점이 있었다. 그러나 본 연구결과 이소플라본은 전립선암 환자의 혈중 지질 패턴과 항산화체계를 개선시키는 효과를 보였다. 따라서 이소플라본이 지질대사에 미치는 영향과 항산화작용기전에 대한 보다 심층적인 연구가 이루어져야 할 것이며, 보다 많은 전립선암 환자를 대상으로 이소플라본 섭취에 따른 장기적인 임상실험연구가 이루어져 이소플라본이 전립선암 환자의 삶의 질을 향상시킬 수 있는지에 대한 다각적인 검토가 필요하다고 본다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권5호
• /
• pp.2835-2838
• /
• 2013

Background: Prostate cancer features a substantial incidence and mortality burden, similarly to breast cancer, and it ranks among the top ten specific causes of death in males. Objective: To explore the situation of prostate cancer in a healthy population cohort in Eastern Nepal. Materials and Methods: This study was conducted in the Department of General Surgery at B. P. Koirala Institute of Health Sciences, Dharan, Nepal from July 2010 to June 2011. Males above 50 years visiting the Surgical Outpatient Department in BPKIHS were enrolled in the study and screening camps were organized in four Teaching District Hospitals of BPKIHS, all in Eastern Nepal. Digital rectal examination (DRE) was conducted by trained professionals after collecting blood for assessment of serum prostatic specific antigen (PSA). Trucut biopsies were performed for all individuals with abnormal PSA/DRE findings. Results: A total of 1,521 males more than 50 years of age were assessed and screened after meeting the inclusion criteria. The vast majority of individuals, 1,452 (96.2%), had PSA ${\leq}4.0$ ng/ml. Abnormal PSA (>4 ng/ml) was found in 58 (3.8%). Abnormal DRE was found in 26 (1.72%). DRE and PSA were both abnormal in 26 (1.72%) individuals. On the basis of raised PSA or abnormal DRE 58 (3.84%) individuals were subjected to digitally guided trucut biopsy. Biopsy report revealed benign prostatic hyperplasia in 47 (3.11%) and adenocarcinoma prostate in 11 (0.73%). The specificity of DRE was 66.0%with a sensitivity of 90.9% and a positive predictive value of 38.5%. The sensitivity of PSA more than 4ng/ml in detecting carcinoma prostate was 100% and the positive predictive value for serum PSA was 19.0% Conclusions: The overall cancer detection rate in this study was 0.73% and those detected were locally advanced. Larger community-based studies are highly warranted specially among high-risk groups.

• Biomolecules & Therapeutics
• /
• 제21권1호
• /
• pp.10-20
• /
• 2013

Prostate cancer is one of the most prevalent non-skin related cancers. It is the second leading cause of cancer deaths among males in most Western countries. If prostate cancer is diagnosed in its early stages, there is a higher probability that it will be completely cured. Prostatic acid phosphatase (PAP) is a non-specific phosphomonoesterase synthesized in prostate epithelial cells and its level proportionally increases with prostate cancer progression. PAP was the biochemical diagnostic mainstay for prostate cancer until the introduction of prostate-specific antigen (PSA) which improved the detection of early-stage prostate cancer and largely displaced PAP. Recently, however, there is a renewed interest in PAP because of its usefulness in prognosticating intermediate to high-risk prostate cancers and its success in the immunotherapy of prostate cancer. Although PAP is believed to be a key regulator of prostate cell growth, its exact role in normal prostate as well as detailed molecular mechanism of PAP regulation is still unclear. Here, many different aspects of PAP in prostate cancer are revisited and its emerging roles in other environment are discussed.

• International Journal of Industrial Entomology and Biomaterials
• /
• 제47권2호
• /
• pp.140-146
• /
• 2023

In recent years, the number of patients with benign prostatic hyperplasia (BPH), a condition that commonly occurs in elderly men, has increased due to aging and the adoption of western dietary habits. Treatment with chemical drugs, such as finasteride or dutasteride, can cause side effects such as erectile dysfunction or sexual problems. This necessitates the development of remedies using natural substances derived from food ingredients. In this study, we investigated the inhibitory effects of Oxya chinensis sinuosa hot water extract (OCH) on BPH production in LNCaP cells, a hormone-dependent prostate cancer cell line. We found that the mRNA expression of androgen receptor (AR), prostate specific antigen (PSA), and, 5α-reductases 1, and 2 decreased following treatment with OCH. Furthermore, OCH treatment resulted in reduced protein expression of BPH regulators, such as AR. Collectively, these results suggest that OCH exerts a beneficial effect on BPH by inhibiting the AR signaling pathway, indicating the potential of OCH as a therapeutic agent for the prevention and treatment of BPH.